Contrarily, we observed that when HER2 was no/mild, only 40.32 and 38.71% of malignant tumors showed moderate/intense expression of Smurf2 and CNKSR2 whereas 50.00 and 48.39% of malignant tumors showed moderate/intense expression of Smurf2 and CNKSR2 when HER2 was moderate/intense. This evidence concerns the gene ERBB2 and cancer.